CureVac

Covid-19: the reasons for the failure of the CureVac vaccine candidate
Science

Covid-19: the reasons for the failure of the CureVac vaccine candidate

The candidate vaccine has been put away in the closet. The German laboratory CureVac announced on Tuesday the abandonment of…
Doubts about effectiveness, delays in delivery … CureVac vaccine in disarray
COVID-19

Doubts about effectiveness, delays in delivery … CureVac vaccine in disarray

Surely he will not stand up to the hegemony of the giant Pfizer. The CureVac Covid-19 vaccine, 400 million doses…
CureVac candidate vaccine is only 47% effective, according to interim review
COVID-19

CureVac candidate vaccine is only 47% effective, according to interim review

The vaccine “has achieved a preliminary 47% efficacy against COVID-19, regardless of its severity, and does not meet predetermined statistical…
Covid: CureVac candidate vaccine is only 47% effective, according to interim analysis
COVID-19

Covid: CureVac candidate vaccine is only 47% effective, according to interim analysis

The messenger RNA vaccine does not meet the required criteria at this stage, said the German laboratory, which has signed…
Covid-19: Disappointing First Results from CureVac Vaccine Candidate
COVID-19

Covid-19: Disappointing First Results from CureVac Vaccine Candidate

DELAY – German lab Curevac announced Wednesday that its messenger RNA vaccine candidate is not as effective as expected, especially…
CureVac vaccine expired in Germany
COVID-19

CureVac vaccine expired in Germany

German Minister of Economy Peter Altmeier (left) and State Secretary of the Ministry of Economics Ulrich Nussbaum (right) at a…
Ingmar Hoerr, cofondateur de CureVac : Notre vaccin sera moins cher et plus accessible
Science

Ingmar Hoerr, cofondateur de CureVac : Notre vaccin sera moins cher et plus accessible

La crise du Covid-19 aura au moins eu l’avantage d’accélérer le développement de technologies prometteuses. Parmi elles, les vaccins à…
Back to top button